Van Hauwermeiren Timothy 4

What Happened

• Timothy Van Hauwermeiren, a director of Denali Therapeutics, received equity awards on 2026-06-03 consisting of 6,408 shares and 19,226 derivative units (RSUs), both reported at $0.00. Combined, the grants total 25,634 shares/RSU equivalents. These were awards (code A) — company compensation, not open-market purchases.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (appears timely).
• Grant details: 6,408 shares @ $0.00 (acquired) and 19,226 @ $0.00 (derivative/RSU).
• Holdings after transaction: Not specified in the transaction summary provided in this filing.
• Footnotes:
  • F1: Each derivative unit is an RSU and a contingent right to one share; 100% of these RSUs vest on the earlier of (i) one year after the grant or (ii) the day before the issuer's next annual meeting.
  • F2: The filing notes 17,040 RSUs are unvested.
  • F3: Notes that any option shares (if applicable) vest 100% on the same schedule as above.
• Transaction code: A = Award/Grant.

Context

• These awards are typical director compensation and are reported at $0 because they are grants, not purchases. RSUs are derivative awards that convert into shares if and when they vest; they do not represent immediate open-market buying or selling. Vesting timing (within ~1 year per footnotes) determines when the director will actually receive shares and potentially incur tax events.